康基醫療(09997.HK)附屬與貝朗醫療訂立戰略合作協議
康基醫療(09997.HK)公布,公司之全資附屬杭州康基,與貝朗集團旗下中國子公司貝朗醫療訂立戰略合作協議。雙方同意在產品研發、生產、銷售、市場與營銷及學術推廣等方面開展廣泛合作。
根據合作協議之條款,雙方同意在外科手術設備、微創手術器械及耗材方面開展合作,如通過產品授權、OEM/ODM生產等合作模式為醫生和患者提供更豐富的產品;未來在外科領域中開展深度合作,合作範圍包括但不限於新產品聯合設計及開發、樣品定制加工、技術轉移、共建聯合實驗室、項目孵化等;及雙方將基於各自的優勢資源協助推進彼此部分產品在某些區域的註冊及市場銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.